Investor Highlights

The purpose of the Investment Center is to inform current shareholders or new investors of the growing market opportunities, market developments, and the financial status of our company. The information provided here is intended to help you make an informed decision about your potential investment in Cortex.

SEC XBRL Filings

Q3 2011 Form 10-Q
Cortex Pharmaceuticals, Inc. filed this Form 10-Q on 11/14/11

Document Outline
XBRL Item - EX-101.INS - XBRL Instance Document
XBRL Item - EX-101.SCH - XBRL Taxonomy Extension Schema Document
XBRL Item - EX-101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Item - EX-101.LAB - XBRL Taxonomy Extension Label Linkbase Document
XBRL Item - EX-101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document

Q2 2011 Form 10-Q
Cortex Pharmaceuticals, Inc. filed this Form 10-Q on 08/18/11

Document Outline
XBRL Item - EX-101.INS - XBRL Instance Document
XBRL Item - EX-101.SCH - XBRL Taxonomy Extension Schema Document
XBRL Item - EX-101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Item - EX-101.LAB - XBRL Taxonomy Extension Label Linkbase Document
XBRL Item - EX-101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document

• Download Cortex Form 10-K fiscal year ended December 31, 2010 – 381kb – (03/22/11)
  
  If you would prefer to receive a copy by mail, please call us at (800) 949-3019 (x100).
  You may also send an email request or fax us at (949) 727-3657.
  
  
• Proxy Statement – 196kb PDF – (4/12/10)
  
  
• Audit Committee Charter
  
  
• Compensation Committee Charter
  
  
• Governance and Nominations Committee Charter
  
  
• Research and Development Committee Charter
  
  
• Stock Incentive Plan – 64kb PDF – (5/10/06)
  
  
• SEC Filings

Safe Harbor Statement
This investor package includes information that may contain forward-looking statements concerning the Company’s patent portfolio, research and development activities and business activities. Actual results may differ materially, depending on a number of risk factors, including the risks that that competitors may challenge or design around the Company’s patents or develop competing technologies; that the Company may be unable to secure additional capital needed to continue its operations; that the Company may be unable to arrive at corporate partnerships with larger pharmaceutical companies on acceptable terms and therefore be required to independently fund clinical development of AMPAKINE compounds through the sale of additional equity securities or otherwise; that the Company’s proposed products may be unsafe or ineffective for any or all of their proposed indications; and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company’s Securities and Exchange Commission filings, the Company’s proposed products would require additional research, lengthy and costly clinical testing and regulatory approval. The AMPAKINE compounds are investigational drugs and have not yet been shown to have efficacy in the treatment of any disease.